Treating Bipolar Disease Using Racemic Mixtures of Valnoctamide

Bialer Meir, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research


  • A bipolar disorder is a form of a depressive disease that characteristically involves cycles of depression and elation or mania. The disorder is often a chronic recurring condition deteriorating one’s quality of life.
  • Valnoctamide (VCD), an amide analogue of VPAhaving anti-convulsant activity, was found to be distinctly less teratogenic than Valproic acid  (VPA), thus enabling its use for treating bipolar disorder for young women. There is a need for non-teratogenic bipolar treatment.

Our Innovation

  • The technology applies to the use of racemic valnoctamide (VCD) for the treatment of bipolar disorder, including the manic phase, for young women of childbearing age. 
  • The researchers analyzed Valnoctamide (VCD) which is a VPA derivative with low teratogenic potential and presumably lower side effects
  • The novel compound includes pharmaceutically acceptable salts, hydrates and solvates thereof, for the preparation of a medicament for treating a bipolar disorder, most preferably the manic phase of bipolar disease. The racemic mixtures containing equal amounts (25%) of each of the 4 stereoisomers of the compound were studied for a pharmaceutical composition for the treatment of a bipolar disorder, prefer ably the manic phase of a bipolar disorder.


  • May eliminate other side effects of bipolar treatment such as hepatotoxicity, sedation and weight gain 
  • Proven clinical benefit over current treatment


Figure 1 Valnoctamide efficacy Vs. Placebo as add on to risperidone in acute mania



Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: